Absolute Agreement Between Subjective Hand Squeeze and Objective Handgrip Strength in Adults.

Kieser, J, Langford, M, Stover, E, Tomkinson, GR, Clark, BC, Cawthon, PM, and McGrath, R. Absolute agreement between subjective hand squeeze and objective handgrip strength in adults. J Strength Cond Res 39(1): 16-23, 2025-Despite handgrip strength (HGS) being considered a convenient muscle strength assessment, HGS lacks routine measurement in sports medicine and healthcare settings because barriers such as time and lack of instrumentation may exist.

Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections.

Introduction: Dysregulated host cytokine responses to SARS-CoV-2 infection are a primary cause of progression to severe disease, whereas early neutralizing antibody responses are considered protective. However, there are gaps in understanding the early temporal dynamics of these immune responses, and the profile of productive immune responses generated by non-hospitalized people with mild infections in the community.

Methods: Here we conducted a prospective cohort study of people with suspected infections/exposures in the US state of North Carolina, before vaccine availability.

Vaccination with antigenically complex hemagglutinin mixtures confers broad protection from influenza disease.

Current seasonal influenza virus vaccines induce responses primarily against immunodominant but highly plastic epitopes in the globular head of the hemagglutinin (HA) glycoprotein. Because of viral antigenic drift at these sites, vaccines need to be updated and readministered annually. To increase the breadth of influenza vaccine-mediated protection, we developed an antigenically complex mixture of recombinant HAs designed to redirect immune responses to more conserved domains of the protein.

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Purpose: The multicenter, open-label, randomized phase 2 NCI-9944 study (NCT02595892) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank = .044, which met the one-sided significance level of 0.